Abstract
The mucosal surface is the largest route through which pathogens enter the human body. To control the outbreak of mucosal infectious diseases, we must use our knowledge of the mucosal immune system to create vaccines that elicit protective mucosal and systemic immunity. Mucosal vaccines have advantages over traditional injectable vaccines in that they not only induce effective mucosal immune responses, but they also do not cause physical or psychological discomfort. Mucosal vaccines currently licensed for human use include oral vaccines against Vibrio cholerae, Salmonella typhi, poliovirus and rotavirus, and nasal vaccines against influenza virus. To further improve the existing vaccines, it will be necessary to develop novel vaccine production, storage and delivery systems through innovative strategies derived from interdisciplinary scientific research. Our accumulated knowledge of the innate and acquired arms of the mucosal immune system and the recent scientific and technical advancements in the fields of molecular biology, plant biology, bio-engineering and chemical engineering, genome biology and systems biology have created a unique research and development platform for the development of the next generation of mucosal vaccines. This review summarizes the current perspectives and future directions of mucosal vaccine development with emphasis on oral and nasal vaccines for the control of infectious diseases.
| Original language | English |
|---|---|
| Article number | dxu063 |
| Pages (from-to) | 517-528 |
| Number of pages | 12 |
| Journal | International Immunology |
| Volume | 26 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- MucoRice
- Nasal vaccine
- Oral vaccine
- Rice-based vaccine
ASJC Scopus subject areas
- Immunology
- Medicine(all)
Cite this
Challenges in mucosal vaccines for the control of infectious diseases. / Azegami, Tatsuhiko; Yuki, Yoshikazu; Kiyono, Hiroshi.
In: International Immunology, Vol. 26, No. 9, dxu063, 2014, p. 517-528.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Challenges in mucosal vaccines for the control of infectious diseases
AU - Azegami, Tatsuhiko
AU - Yuki, Yoshikazu
AU - Kiyono, Hiroshi
PY - 2014
Y1 - 2014
N2 - The mucosal surface is the largest route through which pathogens enter the human body. To control the outbreak of mucosal infectious diseases, we must use our knowledge of the mucosal immune system to create vaccines that elicit protective mucosal and systemic immunity. Mucosal vaccines have advantages over traditional injectable vaccines in that they not only induce effective mucosal immune responses, but they also do not cause physical or psychological discomfort. Mucosal vaccines currently licensed for human use include oral vaccines against Vibrio cholerae, Salmonella typhi, poliovirus and rotavirus, and nasal vaccines against influenza virus. To further improve the existing vaccines, it will be necessary to develop novel vaccine production, storage and delivery systems through innovative strategies derived from interdisciplinary scientific research. Our accumulated knowledge of the innate and acquired arms of the mucosal immune system and the recent scientific and technical advancements in the fields of molecular biology, plant biology, bio-engineering and chemical engineering, genome biology and systems biology have created a unique research and development platform for the development of the next generation of mucosal vaccines. This review summarizes the current perspectives and future directions of mucosal vaccine development with emphasis on oral and nasal vaccines for the control of infectious diseases.
AB - The mucosal surface is the largest route through which pathogens enter the human body. To control the outbreak of mucosal infectious diseases, we must use our knowledge of the mucosal immune system to create vaccines that elicit protective mucosal and systemic immunity. Mucosal vaccines have advantages over traditional injectable vaccines in that they not only induce effective mucosal immune responses, but they also do not cause physical or psychological discomfort. Mucosal vaccines currently licensed for human use include oral vaccines against Vibrio cholerae, Salmonella typhi, poliovirus and rotavirus, and nasal vaccines against influenza virus. To further improve the existing vaccines, it will be necessary to develop novel vaccine production, storage and delivery systems through innovative strategies derived from interdisciplinary scientific research. Our accumulated knowledge of the innate and acquired arms of the mucosal immune system and the recent scientific and technical advancements in the fields of molecular biology, plant biology, bio-engineering and chemical engineering, genome biology and systems biology have created a unique research and development platform for the development of the next generation of mucosal vaccines. This review summarizes the current perspectives and future directions of mucosal vaccine development with emphasis on oral and nasal vaccines for the control of infectious diseases.
KW - MucoRice
KW - Nasal vaccine
KW - Oral vaccine
KW - Rice-based vaccine
UR - http://www.scopus.com/inward/record.url?scp=84906829681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906829681&partnerID=8YFLogxK
U2 - 10.1093/intimm/dxu063
DO - 10.1093/intimm/dxu063
M3 - Review article
VL - 26
SP - 517
EP - 528
JO - International Immunology
JF - International Immunology
SN - 0953-8178
IS - 9
M1 - dxu063
ER -